secwatch.observer — SEC 8-K summary
======================================

Issuer:     Panbela Therapeutics, Inc. (—)
CIK:        0001029125
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001437749-24-009416
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Panbela Q4 net loss $6.5M; ASPIRE trial >50% enrolled; cash $2.6M
-----------------------------------------------------------------

- Net loss of $6.5M ($65.90/share) in Q4 2023 vs. $4.7M loss in Q4 2022.
- Cash $2.6M at Dec 31, 2023; raised ~$9M in Jan 2024 registered offering.
- ASPIRE Phase III trial for metastatic pancreatic cancer exceeds 50% enrollment; full enrollment (~600 patients) expected Q1 2025.
- Research and development expense $6.1M in Q4, up from $3.5M year-over-year.
- Divestiture of pediatric neuroblastoma program to US WorldMeds for up to $9.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1029125/000143774924009416/0001437749-24-009416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1029125/000143774924009416/pbla20240326_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer